Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Eos Energy Enterprises Inc (EOSE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Eos Energy Enterprises Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.08 (market cap $8.04B), while Eos Energy Enterprises Inc trades at $4.83 (market cap $1.52B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 5.3× Eos Energy Enterprises Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Eos Energy Enterprises Inc nearer its low. Which is the better fit depends on your goals.
| BIO | EOSE | |
|---|---|---|
Market Cap | $8.04B | $1.52B |
Sector | Health | Energy |
52-Week High | $339.75 | $19.19 |
52-Week Low | $241.71 | $4.29 |
Enterprise Value | $7.85B | $1.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Eos Energy Enterprises (EOSE) trades at $4.35, down 1.14% on the day, amid a bearish technical trend and challenging fundamentals. The company reported a net loss of $969.65 million on $114.20 million in revenue for 2025, with negative gross and net profit margins. However, recent news highlights project wins, including a 400 MWh battery storage selection, and a $125 million investment for its Frontier Power USA platform, signaling growth potential in the long-duration energy storage market.
The outlook is a balance of high execution risk against significant growth opportunity. While analyst consensus is a 'Hold' with a $8.40 price target, the company's path to profitability remains uncertain. Key risks include persistent cash burn and high debt-to-asset ratio, but successful commercialization of its zinc-based battery technology could drive substantial upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →
